Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2026Indian Heart JournalOpen Access

Novel cardiac myosin inhibitors and traditional therapies control symptoms and reduce LVOT gradients in HCM.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with Hypertrophic cardiomyopathy (HCM), including obstructive and non-obstructive types

Design

Review

Key result

Medical management of hypertrophic cardiomyopathy utilizes traditional therapies and novel cardiac myosin inhibitors to provide mechanism-based symptom control and reduce outflow tract gradients.

Authors

MGMohit GuptaVGVrinda GoelMGM.P. Girish

Discussion

Loading...

Member takes

Overview

Mechanism-based HCM therapy warrants clinical consideration; leaves open need for targeted RCTs across phenotypes.

Key Points

  • This review aims to outline effective medical management strategies for hypertrophic cardiomyopathy (HCM).
  • Detailed review of management strategies for obstructive and non-obstructive HCM across current practices.
  • Evaluation of pharmacologic agents including beta-blockers and cardiac myosin inhibitors.
  • Development of a clinical algorithm for practitioner's use.
  • Pharmacotherapy must target specific physiological mechanisms leading to HCM symptoms.
  • Obstructive HCM management emphasizes reducing the LVOT gradient through tailored therapies.
  • The introduction of cardiac myosin inhibitors has marked a notable advancement in HCM treatment.

Structured PICO

P
Population
Patients with Hypertrophic cardiomyopathy (HCM), including obstructive and non-obstructive types
I
Intervention
Medical management including non-vasodilating beta-blockers, non-dihydropyridine calcium-channel blockers, disopyramide, and cardiac myosin inhibitors (mavacamten, aficamten)

This review provides a pragmatic algorithm for the medical management of hypertrophic cardiomyopathy, highlighting the integration of novel cardiac myosin inhibitors with traditional therapies.

Cite This Study

Gupta et al. (2026) conducted a review in Hypertrophic cardiomyopathy. Medical management (including cardiac myosin inhibitors) was evaluated. Medical management of hypertrophic cardiomyopathy utilizes traditional therapies and novel cardiac myosin inhibitors to provide mechanism-based symptom control and reduce outflow tract gradients.

synapsesocial.com/papers/6a358ddb3ed1b5ae34f8a791https://doi.org/10.1016/j.ihj.2026.06.005
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy2025
  2. 2Targeted Therapies in Hypertrophic Cardiomyopathy: A Practical Review of Evidence, Implementation, and Innovation2026
  3. 3Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions2025 · 2 citations
  4. 4INNOVATIVE DIAGNOSTIC TECHNOLOGIES AND TARGETED THERAPEUTICS IN HYPERTROPHIC CARDIOMYOPATHY: IMPLICATIONS FOR PERSONALIZED PATIENT CARE2025
  5. 5Hypertrophic Cardiomyopathy: Current Perspectives2025